About Us
About Guard Therapeutics
Vision, Business Model & Goal
The Board
Management
Research
Kidney disease
Science
Pipeline
RMC-035
GTX Peptides
Investor Relations
Financial calender
Financial reports
Share information
Corporate governance
General meetings
Newsroom
Press releases
Event calender
Analyses and presentations
Subscribe
Contact
Swe
Search
Novel Therapies Targeting Kidney Disease
Latest Press Releases
First patient in Europe dosed in the clinical phase 2b POINTER study
Read more
Guard Therapeutics announces outcome in rights issue
(regulatory)
Read more
Guard Therapeutics phase 2 results published in leading scientific journal
Read more
Press releases
16 Oct 2024
First patient in Europe dosed in the clinical phase 2b POINTER study
Read more
24 Sep 2024 · Regulatory information
Guard Therapeutics announces outcome in rights issue
Read more
17 Sep 2024
Guard Therapeutics phase 2 results published in leading scientific journal
Read more
02 Sep 2024 · Regulatory information
Guard Therapeutics publishes prospectus due to upcoming rights issue
Read more
Show more
In focus
17 Oct 2024 / Presentation
Guard presents at Redeye Theme "Cardiovascular & Metabolic Diseases Event 2024"
Read more
23 Sep 2024 / Presentation
CEO Tobias Agervald appears on BiotechTV
Read more
19 Sep 2024 / Presentation
Presentation at Pareto Securities' 15th Annual Healthcare Conference
Read more
30 Jan 2024 / Presentation
Guard Therapeutics R&D update January 30, 2024
Read more
Show more
Upcoming events
20 Feb 2025
Year-end report 2024
Read more
Show more
Event calendar
/
Financial calendar